103.33
0.33%
0.24
Schlusskurs vom Vortag:
$103.09
Offen:
$103.16
24-Stunden-Volumen:
318.92K
Relative Volume:
0.29
Marktkapitalisierung:
$206.46B
Einnahmen:
$49.94B
Nettoeinkommen (Verlust:
$17.60B
KGV:
27.78
EPS:
3.72
Netto-Cashflow:
$12.51B
1W Leistung:
+0.03%
1M Leistung:
-10.62%
6M Leistung:
+0.58%
1J Leistung:
+7.32%
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
NVS | 103.37 | 206.46B | 49.94B | 17.60B | 12.51B | 3.72 |
LLY | 738.36 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 101.75 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 153.09 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 167.72 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 97.05 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
2022-12-05 | Hochstufung | Stifel | Hold → Buy |
2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | Fortgesetzt | Citigroup | Buy |
2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
2021-03-10 | Herabstufung | Argus | Buy → Hold |
2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-09-10 | Hochstufung | UBS | Neutral → Buy |
2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
2019-04-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-12-11 | Fortgesetzt | Jefferies | Buy |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-01-25 | Bestätigt | Leerink Partners | Outperform |
2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Weekly Upgrades and Downgrades - InvestorPlace
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Novartis ranks first in 2024 Access to Medicine Index - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis at ASH - Novartis
Novartis 2022 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Translational medicine research at Novartis - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
Germany Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
21 Best Healthcare Companies to Invest In - Morningstar
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Novartis lower as BofA downgrades on risks to valuation - MSN
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):